Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 3
2006 4
2007 4
2008 5
2009 4
2010 5
2011 4
2012 8
2013 11
2014 10
2015 7
2016 11
2017 12
2018 8
2019 17
2020 31
2021 23
2022 19
2023 22
2024 13
2025 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

202 results

Results by year

Filters applied: . Clear all
Page 1
Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research.
Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F, Groenvold M, van Leeuwen M, Petersen MA, Ramage J, Tomaszewski KA, Young T, Holzner B; EORTC Quality of Life Group. Giesinger JM, et al. Among authors: caocci g. J Clin Epidemiol. 2020 Feb;118:1-8. doi: 10.1016/j.jclinepi.2019.10.003. Epub 2019 Oct 19. J Clin Epidemiol. 2020. PMID: 31639445 Free article.
HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia.
Caocci G, Greco M, Arras M, Cusano R, Orrù S, Martino B, Abruzzese E, Galimberti S, Mulas O, Trucas M, Littera R, Lai S, Carcassi C, La Nasa G. Caocci G, et al. Leuk Res. 2017 Oct;61:1-5. doi: 10.1016/j.leukres.2017.08.005. Epub 2017 Aug 18. Leuk Res. 2017. PMID: 28841441
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study.
Palandri F, Breccia M, Morsia E, Elli EM, Benevolo G, Tiribelli M, Beggiato E, Farina M, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Isidori A, Dedola A, Scalzulli E, Moioli A, Cavalca F, Caserta S, Duminuco A, Martino B, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Bonifacio M, Palumbo GA, Branzanti F, Iurlo A, Abruzzese E. Palandri F, et al. Among authors: caocci g. Leuk Res. 2025 Jul;154:107719. doi: 10.1016/j.leukres.2025.107719. Epub 2025 May 27. Leuk Res. 2025. PMID: 40460507 No abstract available.
Immunological deregulation in classic hodgkin lymphoma.
Romano A, Vetro C, Caocci G, Greco M, Parrinello NL, Di Raimondo F, La Nasa G. Romano A, et al. Among authors: caocci g. Mediterr J Hematol Infect Dis. 2014 Jun 1;6(1):e2014039. doi: 10.4084/MJHID.2014.039. eCollection 2014. Mediterr J Hematol Infect Dis. 2014. PMID: 24959336 Free PMC article. Review.
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.
Palandri F, Branzanti F, Bonifacio M, Elli EM, Morsia E, Farina M, Tiribelli M, Benevolo G, Beggiato E, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Isidori A, Dedola A, Scalzulli E, Duminuco A, Tosoni L, Strazimiri A, Lemoli RM, Cilloni D, Bocchia M, Pane F, Sartor C, Heidel FH, Breccia M, Palumbo GA, Kuykendall AT. Palandri F, et al. Among authors: caocci g. Cancer. 2025 Sep 1;131(17):e70062. doi: 10.1002/cncr.70062. Cancer. 2025. PMID: 40839414 Free PMC article.
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.
Palandri F, Elli EM, Morsia E, Benevolo G, Tiribelli M, Beggiato E, Bonifacio M, Farina M, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Iurlo A, Isidori A, Bosi C, Guglielmana V, Venturi M, Dedola A, Loffredo M, Fontana G, Duminuco A, Moioli A, Tosoni L, Scalzulli E, Cattaneo D, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Vianelli N, Cavo M, Palumbo GA, Branzanti F, Breccia M. Palandri F, et al. Among authors: caocci g. Cancer. 2024 Dec 15;130(24):4257-4266. doi: 10.1002/cncr.35489. Epub 2024 Jul 30. Cancer. 2024. PMID: 39078647 Free PMC article.
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
Efficace F, Cottone F, Yanez B, Kota V, Castagnetti F, Caocci G, Bonifacio M, Patriarca A, Capodanno I, Miggiano MC, Tiribelli M, Breccia M, Luciano L, Giai V, Iurlo A, Abruzzese E, Fava C, Dinner S, Altman JK, Rosti G, Cortes J, Vignetti M, Cella D. Efficace F, et al. Among authors: caocci g. Cancer. 2024 Jan;130(2):287-299. doi: 10.1002/cncr.35021. Epub 2023 Oct 6. Cancer. 2024. PMID: 37801052 Free PMC article. Clinical Trial.
Response to Dr. Ying Cui comments.
Mulas O, Efficace F, Costa A, Baldi T, Zerbini F, Mantovani D, Morelli E, Perra D, La Nasa G, Caocci G. Mulas O, et al. Among authors: caocci g. Ann Hematol. 2024 Sep;103(9):3829. doi: 10.1007/s00277-024-05914-6. Epub 2024 Jul 30. Ann Hematol. 2024. PMID: 39078436 No abstract available.
202 results